Back to Market返回行情

EHAB Enhabit, Inc.

USHealthcare
$13.80+0.07%ClosedMarket Cap: $706.9M

As of 2026-05-14 16:00

Why EHAB matters now

Enhabit, Inc. (EHAB) is a US stock in Healthcare. The latest InvestLog snapshot shows $13.80 with +0.07% on the session and $706.9M in market capitalization; recent performance reads 1-month +0.07% and YTD +49.67%.

The latest financial table shown here is Q1 2026, with revenue of $264.8M, net income of $19.2M, and EPS of $0.36. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield 11.4%.

The latest indexable market news headline is "Enhabit Home Health & Hospice Announces New Chief Executive Officer" from Business Wire.

Additional event context on this page matters because analyst consensus is Hold with a median target of $13.80; recent insider activity includes Bolton Jeffrey filing D-Return. These signals are research inputs, not a recommendation.

Valuation

P/E (TTM)

PEG

P/B

1.28

P/S

0.66

EV/EBITDA

18.80

DCF Value

$6.23

FCF Yield

11.4%

Div Yield

0.0%

Margins & Returns

Gross Margin

47.9%

Operating Margin

7.2%

Net Margin

-0.3%

ROE

-0.6%

ROA

-0.3%

ROIC

-1.6%

Financials

PeriodRevenueNet IncomeEPS
Q1 2026$264.8M$19.2M$0.36
Q4 2025$270.4M$-38.7M$-0.76
FY 2025$1.06B$-4.6M$-0.09
Q3 2025$263.6M$11.1M$0.22

Analyst Ratings

Consensus

Hold

Target (Consensus)

$13.53

Target (Median)

$13.80

Target Range

$12.00 - $14.00

Strong Buy: 0Buy: 0Hold: 6Sell: 0Strong Sell: 0
TD CowenHold
2026-03-06
UBSNeutral
2026-02-24
JefferiesHold
2026-02-23
Leerink PartnersMarket Perform
2026-02-23
OppenheimerOutperform
2026-01-22

Trading Activity

Insider Trades

Bolton Jeffreydirector
Sell2026-05-15
Bolton Jeffreydirector
Sell2026-05-15
Schochet Barry P.director
Sell2026-05-15
Schochet Barry P.director
Sell2026-05-15
ELSON CHARLES Mdirector
Sell2026-05-15

Company Info

Sector

Healthcare

Industry

Medical - Care Facilities

Country

US

Exchange

Beta

0.96

Enhabit, Inc. operates as a U.S.-based provider of home healthcare and hospice services. Its comprehensive home health division offers various services, such as patient education, pain management, wound care (including dressing changes), cardiac rehabilitation, infusion therapy, pharmaceutical administration, and expert observation and assessment. The company specializes in managing chronic conditions like diabetes, hypertension, arthritis, Alzheimer's disease, low vision, spinal stenosis, Parkinson's disease, osteoporosis, complex wound care, and persistent pain. Additionally, Enhabit provides tailored disease-specific plans for individuals with diabetes, congestive heart failure, those recovering from orthopedic surgery or injuries, and patients with respiratory illnesses. Complementing these medical offerings, licensed physical, occupational, and speech therapists deliver vital rehabilitative support. Beyond home health, Enhabit delivers extensive hospice services designed to meet the physical, emotional, spiritual, and psychosocial needs of terminally ill patients and their families. These services encompass pain and symptom control, palliative and dietary counseling, social worker visits, spiritual guidance, and bereavement support. As of March 31, 2022, Enhabit maintained a significant operational footprint, with 252 home health agencies and 99 hospice agencies spread across 34 states. Established in 2014 and headquartered in Dallas, Texas, the company was previously known as Encompass Health Home Health Holdings, Inc., officially rebranding to Enhabit, Inc. in March 2022. Enhabit, Inc. began operating as a completely independent entity on July 1, 2022.